USA - engelsk - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tr

USA - engelsk - NLM (National Library of Medicine)

zydus lifesciences limited - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tr

USA - engelsk - NLM (National Library of Medicine)

american health packaging - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 10 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in pa

USA - engelsk - NLM (National Library of Medicine)

pai holdings, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 1100 mg in 5 ml - potassium citrate and citric acid oral solution usp is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting and tolerable, even when administered for l

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - potassium citrate; citric acid monohydrate - oral solution - 300mg/1ml ; 50mg/1ml

USA - engelsk - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate, sodium citrate and citric acid oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders. this product is highly concentrated and when administered after meals and before bedtime, allows one to maintain an alkaline urine ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosages. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion. severe renal impairment with ol

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - potassium citrate; citric acid monohydrate - oral solution - 300mg/1ml ; 50mg/1ml

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - potassium citrate; citric acid monohydrate - oral solution - 300mg/1ml ; 50mg/1ml

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

colgate-palmolive limited (nz) - potassium citrate monohydrate 5.53%{relative};  ; sodium monofluorophosphate 0.76%{relative};  ;  ;  ; zinc citrate 2%{relative};   - toothpaste - active: potassium citrate monohydrate 5.53%{relative}   sodium monofluorophosphate 0.76%{relative}       zinc citrate 2%{relative}   excipient: carmellose sodium spearmint flavour green (k91-5943) glycerol dental type silica (hisil da95 synth. amorphous ppt silica) dental type silica (sorbosil ac43 synth. amophous ppt silica) dental type silica (hisil dt267 synth. amorphous ppt silica) macrogol 600 methoxyethylene-maleic anhydride copolymer ponceau 4r potassium hydroxide potassium pyrophosphate purified water saccharin sodium sodium laurilsulfate sorbitol titanium dioxide xanthan gum

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

colgate-palmolive limited (nz) - potassium citrate monohydrate 5.53%{relative};  ; sodium monofluorophosphate 0.76%{relative};  ;   - toothpaste - 0.76% w/w - active: potassium citrate monohydrate 5.53%{relative}   sodium monofluorophosphate 0.76%{relative}     excipient: brilliant blue fcf carmellose sodium glycerol dental type silica (hisil da95) dental type silica (sorbosil ac43) dental type silica (hisil dt267) spearmint flavour green k91-5943 macrogol 600 methoxyethylene-maleic anhydride copolymer purified water saccharin sodium sodium hydroxide sodium laurilsulfate sodium pyrophosphate sorbitol titanium dioxide xanthan gum